Eugenia M. Ramos-Davila
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eugenia M. Ramos-Davila has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Raul Eduardo Ruiz-Lozano
UIC Department of Ophthalmology and Visual Sciences, Chicago, IL, USA
16 shared publications - Alejandro Rodriguez-Garcia
Tecnologico de Monterrey, School of Medicine and Health Sciences, Institute of Ophthalmology and Visual Sciences, Monterrey, Mexico
8 shared publications - Lucas Antonio Garza Garza
Tecnologico de Monterrey, School of Medicine and Health Sciences, Institute of Ophthalmology and Visual Sciences, Monterrey, Mexico
6 shared publications - Mariana González-Treviño
Division of Rheumatology Mayo Clinic Rochester Minnesota
6 shared publications - David Gómez-Almaguer
Hematology Service, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, México
5 shared publications - José Carlos Jaime-Pérez
Hematology Department, Internal Medicine Division, Dr. José Eleuterio González University Hospital and School of Medicine, Universidad Autónoma de Nuevo León, Monterrey, Mexico
5 shared publications
Latest Publications
- 29 July 2026
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 315
Radiation retinopathy: a review
- 29 July 2026
- Published by Springer Nature in International Ophthalmology
- Vol. 46 (1) , 315
Radiation retinopathy: a review
- 12 June 2026
- Published by Wolters Kluwer Health in Cornea
Novel PPOX Mutation With Ocular Involvement in Variegate Porphyria: Case Report and Literature Review
Purpose: To report the clinical and histopathologic features of cicatrizing conjunctivitis associated with variegate porphyria (VP). Methods: A comprehensive literature search was performed in PubMed and Google Scholar through September 2025 using terms related to porphyria and ocular involvement. All relevant case reports, series, reviews, original articles, and cited references were included. Results: A 52-year-old woman with a history of seizures, dorsal hand skin lesions, and lower-extremity paresthesia presented with cicatrizing conjunctivitis and corneal opacification with neovascularization. A systemic evaluation demonstrated elevated urinary and fecal porphyrins. Molecular analysis revealed a novel heterozygous 3.49-Mb deletion encompassing the entire protoporphyrinogen oxidase gene. Conjunctival histopathology revealed subepithelial bullae with acanthotic epithelium, and direct immunofluorescence was negative for immune complex deposition. Conclusions: Ocular manifestations in porphyria are rare and have primarily been described in porphyria cutanea tarda and congenital erythropoietic porphyria. A review of the English language literature summarizing reported cases of porphyria-associated cicatrizing conjunctivitis is presented. This report broadens the differential diagnosis of cicatrizing conjunctivitis to include VP.
- 12 June 2026
- Published by Wolters Kluwer Health in Cornea
Novel PPOX Mutation With Ocular Involvement in Variegate Porphyria: Case Report and Literature Review
Purpose: To report the clinical and histopathologic features of cicatrizing conjunctivitis associated with variegate porphyria (VP). Methods: A comprehensive literature search was performed in PubMed and Google Scholar through September 2025 using terms related to porphyria and ocular involvement. All relevant case reports, series, reviews, original articles, and cited references were included. Results: A 52-year-old woman with a history of seizures, dorsal hand skin lesions, and lower-extremity paresthesia presented with cicatrizing conjunctivitis and corneal opacification with neovascularization. A systemic evaluation demonstrated elevated urinary and fecal porphyrins. Molecular analysis revealed a novel heterozygous 3.49-Mb deletion encompassing the entire protoporphyrinogen oxidase gene. Conjunctival histopathology revealed subepithelial bullae with acanthotic epithelium, and direct immunofluorescence was negative for immune complex deposition. Conclusions: Ocular manifestations in porphyria are rare and have primarily been described in porphyria cutanea tarda and congenital erythropoietic porphyria. A review of the English language literature summarizing reported cases of porphyria-associated cicatrizing conjunctivitis is presented. This report broadens the differential diagnosis of cicatrizing conjunctivitis to include VP.
- 20 February 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (3) , 464-472
Clinical Features and Treatment Outcomes of Patients with Tubulointerstitial Nephritis and Uveitis Syndrome: A Case Series
Describe the demographic and clinical characteristics, treatment outcomes, and ocular complications in patients with tubulointerstitial nephritis and uveitis (TINU) syndrome. Retrospective study of TINU patients seen at the Foster Center for Ocular Immunology (Duke University) and Wilmer Eye Institute (Johns Hopkins School of Medicine) between January 2014-December 2023. Patients were diagnosed using the 2021 SUN Working Group criteria. 27 TINU patients, 16 (59%) males, aged 20.4 ± 15.8 (range: 7-71) years were included. The mean follow-up time was 24.3 ± 16.5 (range: 7-75) months. All tested patients had an elevated urinary β2-microglobulin. Ten (37%) patients had positive renal biopsy. Thirteen (48%) patients presented with isolated anterior uveitis, and 14 (52%) had additional intermediate/posterior segment findings in at least one eye. At baseline, all patients were managed with topical corticosteroids (TCS), with 6 (27%) patients requiring oral prednisone (PRD) and 17 (63%) steroid-sparing immunosuppressive therapy (SS-IMT). Inflammatory control was achieved in 26 (96%) patients with TCS only (n = 4), TCS+PRD (n = 5), TCS+SS-IMT (n = 6), and TCS+PRD+SS-IMT (n = 11). Thirteen of 26 patients (50%) developed disease relapse at a mean time of 8.9 ± 18.9 (range: 1-71) months. One patient was lost to follow-up. Eighteen (67%) patients developed TINU-associated ocular complications. Five eyes from 4 patients had a median decrease in visual acuity of 2 Snellen lines (range: 1-4) during follow-up. The demographic and clinical presentation of TINU is heterogeneous. Intermediate and posterior segment manifestations are common. Treatment with topical and systemic corticosteroids only may be insufficient to prevent disease relapse, with most patients requiring long-term immunosuppressive therapy.
- 20 February 2026
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 34 (3) , 464-472
Clinical Features and Treatment Outcomes of Patients with Tubulointerstitial Nephritis and Uveitis Syndrome: A Case Series
Describe the demographic and clinical characteristics, treatment outcomes, and ocular complications in patients with tubulointerstitial nephritis and uveitis (TINU) syndrome. Retrospective study of TINU patients seen at the Foster Center for Ocular Immunology (Duke University) and Wilmer Eye Institute (Johns Hopkins School of Medicine) between January 2014-December 2023. Patients were diagnosed using the 2021 SUN Working Group criteria. 27 TINU patients, 16 (59%) males, aged 20.4 ± 15.8 (range: 7-71) years were included. The mean follow-up time was 24.3 ± 16.5 (range: 7-75) months. All tested patients had an elevated urinary β2-microglobulin. Ten (37%) patients had positive renal biopsy. Thirteen (48%) patients presented with isolated anterior uveitis, and 14 (52%) had additional intermediate/posterior segment findings in at least one eye. At baseline, all patients were managed with topical corticosteroids (TCS), with 6 (27%) patients requiring oral prednisone (PRD) and 17 (63%) steroid-sparing immunosuppressive therapy (SS-IMT). Inflammatory control was achieved in 26 (96%) patients with TCS only (n = 4), TCS+PRD (n = 5), TCS+SS-IMT (n = 6), and TCS+PRD+SS-IMT (n = 11). Thirteen of 26 patients (50%) developed disease relapse at a mean time of 8.9 ± 18.9 (range: 1-71) months. One patient was lost to follow-up. Eighteen (67%) patients developed TINU-associated ocular complications. Five eyes from 4 patients had a median decrease in visual acuity of 2 Snellen lines (range: 1-4) during follow-up. The demographic and clinical presentation of TINU is heterogeneous. Intermediate and posterior segment manifestations are common. Treatment with topical and systemic corticosteroids only may be insufficient to prevent disease relapse, with most patients requiring long-term immunosuppressive therapy.
- Open Access
- 29 May 2025
- Published by Springer Nature in Journal of Ophthalmic Inflammation and Infection
- Vol. 15 (1) , 1-7
Childhood-onset ocular mucous membrane pemphigoid presenting with peripheral ulcerative keratitis: a case report and review of the literature
Purpose: The purpose of this study was to describe the case of a pediatric patient diagnosed with mucous membrane pemphigoid (MMP) with exclusive ocular involvement presenting at diagnosis with peripheral ulcerative keratitis and provide a review of the literature. Methods: A 12-year-old girl presented with cicatricial conjunctivitis and peripheral ulcerative keratitis (PUK). A conjunctival biopsy and direct immunofluorescence revealed linear deposits of IgG, IgM, and C3 at the basement membrane zone, confirming a diagnosis of ocular MMP. Results: The patient was initially treated with dapsone 25 mg/day and prednisone 40 mg/day along with topical treatment including cyclosporine 0.05%, loteprednol etabonate 0.05%, and sodium hyaluronate 0.15% and trehalose 3%. Inflammation persisted as an increase in the extension of symblepharon was documented. Subsequently, dapsone was switched to oral methotrexate 15 mg/week and prednisone was successfully tapered to 5 mg/day. After three years of follow-up, disease activity remained quiescent. Conclusions: Pediatric mucous membrane pemphigoid with ocular involvement is a rare condition of which few reports have been published, resulting in scarce information regarding its clinical course and response to treatment. We report the first case observed in a Hispanic patient, opening with peripheral ulcerative keratitis, and responding successfully to methotrexate.
- 29 May 2025
- Published by Springer Nature in Journal of Ophthalmic Inflammation and Infection
- Vol. 15 (1) , 1-7
Open AccessChildhood-onset ocular mucous membrane pemphigoid presenting with peripheral ulcerative keratitis: a case report and review of the literature
Purpose: The purpose of this study was to describe the case of a pediatric patient diagnosed with mucous membrane pemphigoid (MMP) with exclusive ocular involvement presenting at diagnosis with peripheral ulcerative keratitis and provide a review of the literature. Methods: A 12-year-old girl presented with cicatricial conjunctivitis and peripheral ulcerative keratitis (PUK). A conjunctival biopsy and direct immunofluorescence revealed linear deposits of IgG, IgM, and C3 at the basement membrane zone, confirming a diagnosis of ocular MMP. Results: The patient was initially treated with dapsone 25 mg/day and prednisone 40 mg/day along with topical treatment including cyclosporine 0.05%, loteprednol etabonate 0.05%, and sodium hyaluronate 0.15% and trehalose 3%. Inflammation persisted as an increase in the extension of symblepharon was documented. Subsequently, dapsone was switched to oral methotrexate 15 mg/week and prednisone was successfully tapered to 5 mg/day. After three years of follow-up, disease activity remained quiescent. Conclusions: Pediatric mucous membrane pemphigoid with ocular involvement is a rare condition of which few reports have been published, resulting in scarce information regarding its clinical course and response to treatment. We report the first case observed in a Hispanic patient, opening with peripheral ulcerative keratitis, and responding successfully to methotrexate.
- 17 December 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 271, 407-416
Comparative Evaluation of the Corneal Sensitivity Thresholds between the Novel Non-Contact and Cochet-Bonnet Esthesiometers
- 17 December 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 271, 407-416
Comparative Evaluation of the Corneal Sensitivity Thresholds between the Novel Non-Contact and Cochet-Bonnet Esthesiometers
- 8 November 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 33 (4) , 570-577
Vogt-Koyanagi-Harada Disease Presenting as Papillitis vs. Classic Serous Retinal Detachment: A Comparative Analysis of Outcomes
To compare the treatment outcome and visual prognosis of Vogt-Koyanagi-Harada (VKH) disease presenting as papillitis vs. serous retinal detachment (SRD). Retrospective comparative cohort study of 35 patients with previously unknown VKH diagnosis, followed-up for ≥6 months. Outcomes measured: (1) time to achieve inflammatory control; (2) VKH relapse; (3) ocular complications (glaucoma, sunset glow fundus, cataract, and vision loss ≥2 Snellen lines); and (4) chances for developing a chronic-recurrent disease. Females predominated in both groups: 12/16 (75%) papillitis and 18/19 (94.7%) SRD. The mean age at presentation was 29 ± 12 years in the papillitis and 36 ± 14 years in the SRD group (p = 0.119), with an overall median follow-up of 26 months (6-180 months). The papillitis-onset VKH group's mean time elapsed between symptoms onset and initial treatment was shorter (2.9 ± 1.0 vs. 4.6 ± 2.8 weeks, p = 0.024). Anterior segment inflammation was lower (56% vs. 79%, p = 0.018), requiring a shorter corticosteroids treatment duration (12.8 ± 16.1 vs. 32.7 ± 34.1 months, p = 0.040), achieving an earlier inflammatory control (1.9 ± 0.6 vs. 4.1 ± 3.2 months, p p p p = 0.017), ocular complications (OR: 19.60, 95% CI: 3.24-118.50, p = 0.001), and chronic-recurrent disease (OR: 20.63; 95% CI: 2.24-189.84, p = 0.008). Mexican-mestizo VKH patients with papillitis-onset VKH disease showed earlier inflammatory control, fewer recurrences, and better visual and ocular complication outcomes.
- 8 November 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 33 (4) , 570-577
Vogt-Koyanagi-Harada Disease Presenting as Papillitis vs. Classic Serous Retinal Detachment: A Comparative Analysis of Outcomes
To compare the treatment outcome and visual prognosis of Vogt-Koyanagi-Harada (VKH) disease presenting as papillitis vs. serous retinal detachment (SRD). Retrospective comparative cohort study of 35 patients with previously unknown VKH diagnosis, followed-up for ≥6 months. Outcomes measured: (1) time to achieve inflammatory control; (2) VKH relapse; (3) ocular complications (glaucoma, sunset glow fundus, cataract, and vision loss ≥2 Snellen lines); and (4) chances for developing a chronic-recurrent disease. Females predominated in both groups: 12/16 (75%) papillitis and 18/19 (94.7%) SRD. The mean age at presentation was 29 ± 12 years in the papillitis and 36 ± 14 years in the SRD group (p = 0.119), with an overall median follow-up of 26 months (6-180 months). The papillitis-onset VKH group's mean time elapsed between symptoms onset and initial treatment was shorter (2.9 ± 1.0 vs. 4.6 ± 2.8 weeks, p = 0.024). Anterior segment inflammation was lower (56% vs. 79%, p = 0.018), requiring a shorter corticosteroids treatment duration (12.8 ± 16.1 vs. 32.7 ± 34.1 months, p = 0.040), achieving an earlier inflammatory control (1.9 ± 0.6 vs. 4.1 ± 3.2 months, p p p p = 0.017), ocular complications (OR: 19.60, 95% CI: 3.24-118.50, p = 0.001), and chronic-recurrent disease (OR: 20.63; 95% CI: 2.24-189.84, p = 0.008). Mexican-mestizo VKH patients with papillitis-onset VKH disease showed earlier inflammatory control, fewer recurrences, and better visual and ocular complication outcomes.
- Open Access
- 2 November 2024
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 14 (1) , 55-71
Validation of the Zarit Burden Interview in Informal Caregivers of Patients with Severe Visual Impairment and Blindness
Introduction The needs of family caregivers providing care to relatives with visual impairment are often dismissed, leading to caregiver burden. The Zarit Burden Interview (ZBI) can measure the caregiver burden of caring for a family member with vision impairment. The purpose of this study is to validate the ZBI in Mexican family caregivers of patients with visual impairment. Methods The ZBI was applied to 137 family caregivers of patients with visual acuity ≤ 20/200 in the best eye for ≥ 6 months. The ZBI’s reliability was determined using Cronbach’s α and the factor structure using exploratory factor analysis (EFA, principal axis factoring with promax rotation). Items with loadings < 0.400 were eliminated. Retained factors were determined using the scree test and Horn’s parallel analysis (95% CI). Associations between burden factors and other variables were evaluated with descriptive and inferential statistics. Results Mean ZBI score was 26.2 ± 13.1, and internal consistency was high (α = 0.871). EFA yielded four factors: (1) embarrassment and frustration, (2) self-efficacy expectations, (3) interference in personal relationships, and (4) personal strain. The α values ranged from 0.649 to 0.812. Spousal caregivers had significantly higher scores (factors 1, 2, and 4), whereas adult children had less scores (factor 3). There was a significant positive correlation between hours of daily caregiving and factors 2 (r = 0.350) and 3 (r = 0.388). A worse degree of visual impairment was associated with higher mean factor scores in all factors. Conclusions The ZBI is a valid instrument to detect burden in Mexican caregivers of patients with visual impairment. We identified a four-factor structure that improved our understanding of the ZBI’s underlying constructs. Interventions targeting specific types of burden are warranted.
- 2 November 2024
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 14 (1) , 55-71
Open AccessValidation of the Zarit Burden Interview in Informal Caregivers of Patients with Severe Visual Impairment and Blindness
Introduction The needs of family caregivers providing care to relatives with visual impairment are often dismissed, leading to caregiver burden. The Zarit Burden Interview (ZBI) can measure the caregiver burden of caring for a family member with vision impairment. The purpose of this study is to validate the ZBI in Mexican family caregivers of patients with visual impairment. Methods The ZBI was applied to 137 family caregivers of patients with visual acuity ≤ 20/200 in the best eye for ≥ 6 months. The ZBI’s reliability was determined using Cronbach’s α and the factor structure using exploratory factor analysis (EFA, principal axis factoring with promax rotation). Items with loadings < 0.400 were eliminated. Retained factors were determined using the scree test and Horn’s parallel analysis (95% CI). Associations between burden factors and other variables were evaluated with descriptive and inferential statistics. Results Mean ZBI score was 26.2 ± 13.1, and internal consistency was high (α = 0.871). EFA yielded four factors: (1) embarrassment and frustration, (2) self-efficacy expectations, (3) interference in personal relationships, and (4) personal strain. The α values ranged from 0.649 to 0.812. Spousal caregivers had significantly higher scores (factors 1, 2, and 4), whereas adult children had less scores (factor 3). There was a significant positive correlation between hours of daily caregiving and factors 2 (r = 0.350) and 3 (r = 0.388). A worse degree of visual impairment was associated with higher mean factor scores in all factors. Conclusions The ZBI is a valid instrument to detect burden in Mexican caregivers of patients with visual impairment. We identified a four-factor structure that improved our understanding of the ZBI’s underlying constructs. Interventions targeting specific types of burden are warranted.
- 24 September 2024
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (3) , 263-271
Clinical Implications of Ultrasound-Based Morphology in Choroidal Melanoma
- 24 September 2024
- Published by Elsevier in Ophthalmology Retina
- Vol. 9 (3) , 263-271
Clinical Implications of Ultrasound-Based Morphology in Choroidal Melanoma
- 17 May 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 33 (1) , 65-71
Clinical Course and Outcomes of Autoimmune Versus Non-Autoimmune Surgically Induced Scleral Necrosis: A Multicentric Comparative Study
To analyze the clinical course and outcomes of autoimmune vs. non-autoimmune surgically induced scleral necrosis (SISN). Multicentric, retrospective, comparative cohort study. Eighty-two eyes of 70 patients with SISN were classified according to pathogenic mechanism into autoimmune vs. non-autoimmune. Main outcome measures included necrosis onset, type of surgery, associated systemic disease, visual acuity, and treatment were analysed in patients followed for ≥ 6 months. Forty-six (65.7%) patients were women, and the median age was 66 (range: 24-90) years. Most patients (82.9%) had unilateral disease. The median time between surgery and SISN onset was 58 (1-480) months. Thirty-one (37.8%) eyes were classified as autoimmune, and 51 (62.2%) as non-autoimmune SISN. Autoimmune SISN was associated with a shorter time between the surgical procedure and SISN onset than non-autoimmune cases (median of 26 vs. 60 months, p = 0.024). Also, autoimmune SISN was associated with cataract extraction (93.5% vs. 25.5%, p < 0.001), severe scleral inflammation (58.1% vs. 17.6%, p < 0.001), and higher incidence of ocular complications (67.7% vs. 33.3%, p = 0.002) than non-autoimmune cases. Remission was achieved with medical management alone in 44 (86.3%) eyes from the non-autoimmune and in 27 (87.1%) from the autoimmune group (p = 0.916). Surgical management was required in 11 (13.4%) eyes, including two requiring enucleations due to scleral perforation and phthisis bulbi. Eyes with autoimmune SISN had a higher rate of cataract surgery, severe scleral inflammation, and ocular complications. Early SISN diagnosis and appropriate management, based on clinical features and pathogenic mechanisms, are critical to avoid sight-threatening complications.
- 17 May 2024
- Published by Taylor & Francis in Ocular Immunology and Inflammation
- Vol. 33 (1) , 65-71
Clinical Course and Outcomes of Autoimmune Versus Non-Autoimmune Surgically Induced Scleral Necrosis: A Multicentric Comparative Study
To analyze the clinical course and outcomes of autoimmune vs. non-autoimmune surgically induced scleral necrosis (SISN). Multicentric, retrospective, comparative cohort study. Eighty-two eyes of 70 patients with SISN were classified according to pathogenic mechanism into autoimmune vs. non-autoimmune. Main outcome measures included necrosis onset, type of surgery, associated systemic disease, visual acuity, and treatment were analysed in patients followed for ≥ 6 months. Forty-six (65.7%) patients were women, and the median age was 66 (range: 24-90) years. Most patients (82.9%) had unilateral disease. The median time between surgery and SISN onset was 58 (1-480) months. Thirty-one (37.8%) eyes were classified as autoimmune, and 51 (62.2%) as non-autoimmune SISN. Autoimmune SISN was associated with a shorter time between the surgical procedure and SISN onset than non-autoimmune cases (median of 26 vs. 60 months, p = 0.024). Also, autoimmune SISN was associated with cataract extraction (93.5% vs. 25.5%, p < 0.001), severe scleral inflammation (58.1% vs. 17.6%, p < 0.001), and higher incidence of ocular complications (67.7% vs. 33.3%, p = 0.002) than non-autoimmune cases. Remission was achieved with medical management alone in 44 (86.3%) eyes from the non-autoimmune and in 27 (87.1%) from the autoimmune group (p = 0.916). Surgical management was required in 11 (13.4%) eyes, including two requiring enucleations due to scleral perforation and phthisis bulbi. Eyes with autoimmune SISN had a higher rate of cataract surgery, severe scleral inflammation, and ocular complications. Early SISN diagnosis and appropriate management, based on clinical features and pathogenic mechanisms, are critical to avoid sight-threatening complications.
- 12 April 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (3) , e3271
Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation
- 12 April 2024
- Published by Wiley in Hematological Oncology
- Vol. 42 (3) , e3271
Outcomes after treating advanced mantle cell lymphoma in a low‐income group at a Latin American center: The role of outpatient hematopoietic stem cell transplantation